A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder

(2013) Stuart A. Montgomery et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder

(2013) Gregory M. Asnis et al.   JOURNAL OF CLINICAL PSYCHIATRY

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

(2013) A.L. Auclair et al.   NEUROPHARMACOLOGY

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale

(2010) David V. Sheehan et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms

(2009) Benji T Kurian et al.   Expert Review of Neurotherapeutics

Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale

(2009) Kathy Harnett Sheehan et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Managing Weight Gain and Metabolic Issues in Patients Treated With Atypical Antipsychotics

(2009) David C. Henderson   JOURNAL OF CLINICAL PSYCHIATRY